CKD: MNT (2010)

Citation:
 
Study Design:
Class:
- Click here for explanation of classification scheme.
Quality Rating:
Research Purpose:

To assess time expended by Registered Dietitians to conduct clinical and research activities during the MDRD Study.

Inclusion Criteria:

Participants in the MDRD Study were divided into 2 groups based on the baseline GFR:

  • Study A included those with moderate renal insufficiency: GFR: 25 – 55 mL/min/1.73m2
  • Study B included those with advanced renal insufficiency: GFR: 13 – 24 mL/min/1.73m2
Exclusion Criteria:

Because the time-log form was developed and implemented during the initial recruitment of participants, some early participant visits were not assessed. 

Description of Study Protocol:

Recruitment:  The MDRD Study was conducted at 15 clinical centers throughout the continental USA.  A total of 840 men and women with chronic renal disease were included in the MDRD Study (details published elsewhere), and time-logs were used from 830 of the total 840 participants for this analysis.  

Design:  The MDRD Study was designed as a 2 x 2 factorial in order to evaluate effects of 3 dietary protein levels and 2 blood pressure levels.

Protein intake

  1. usual: 1.30 g/kg per day
  2. low: 0.58 g/kg per day
  3. very low: 0.28 g/kg per day plus keto-amino acid supplement (also 0.28 g/kg per day)

 Blood pressure levels

  1. usual: 107 mm Hg mean arterial pressure
  2. low: 92 mm Hg mean arterial pressure

Subjects in Study A were randomly assigned to either usual or low dietary protein and usual or low blood pressure goals.  Subjects in Study B were randomly assigned to either low or very low dietary protein and usual or low blood pressure goals.

The time-log form was developed in order to document the time required by the RD in various activities related to effectively achieve the MDRD Study's nutritional objectives.  The nutrition intervention was consistent for all participants and emphasized long term adherence.  Protein intake was of primary focus.  Counseling for weight loss, sodium restriction and fat modification were also included when indicated.

  • The first 4 months of follow up were the most intensive and included instruction in self-monitoring, goal setting, problem solving, food purchasing and eating out.
  • Months 5-24 focused on strengthening knowledge and skills, providing feedback and modeling desired behaviors.
  • Emphasis after month 24 included support activities to maintain motivation, promote self-efficacy, prevent relapse and sustain adherence.  Time-log data was collected through the 36 month visit.

Blinding used:  none reported 

Intervention:  A time-log form was developed, pilot tested and refined during the initial year of recruitment of patients into the MDRD Study.  This time-log form was then completed monthly by the RD for each participant being followed in the MDRD Study with data collected and evaluated in the following categories: 

  • The clinical practice variable included time spent on preparation/follow-up, counseling, charting, telephone calls and patient conferences.
  • The research variable included time spent on food record documentation, anthropometry and other activities specific to the research protocol.

Statistical Analysis:   Descriptive statistics were used to summarize time spent on dietitian activities and total time reported.  One-way ANOVA or two sample t tests were used to compare differences in time by diet group, age, gender, race, education and renal diagnosis.  Because preliminary analyses indicated no significant differences in dietitian time spent for participants in the low protein diet group of Study A compared with Study B, analyses reported in this study reflect combined data of the (A and B) low protein diet groups.  All statistics were calculated using SPSS-X, release 4.0, 1994.  

Data Collection Summary:

Timing of Measurements:  monthly

Dependent Variables: 

  • Time (minutes) spent by the RD in patient counseling, assessed by time per follow-up visit and assessed by time per diet group (ie, usual, low or very low protein intake), measured using the pilot tested time-log form.
  • Dietitian activities were assessed using the following categories:

    • Preparation/follow-up time
    • Counseling
    • Charting
    • Telephone calls
    • Patient conferences
    • Food record documentation
    • Anthropometry
    • Other

Independent Variables

1. Levels of protein intake:

  • usual: 1.30 g/kg per day
  • low: 0.58 g/kg per day
  • very low: 0.28 g/kg per day plus keto-amino acid supplement (also 0.28 g/kg per day)

2.  Blood pressure

Control Variables: 

  • Age
  • Gender
  • Race
  • Marital status
  • Education
  • Renal diagnosis
Description of Actual Data Sample:

Initial N:  The MDRD Study included 840 men and women with chronic renal disease.  Data from time-log forms completed at least once for 830 of the 840 participants were used for this analysis.  Over the 36 months of follow-up, data were included from 19,494 time-logs.

Attrition (Final N):  NA

Age:  18 to 70 years of age 

Ethnicity:  reported elsewhere

Other Relevant Demographics:  gender, race and marital status reported elsewhere, education level included (< 12 years, 12 years, or > 12 years).

Anthropometrics:  reported elsewhere

Location:  continental USA

Summary of Results:

Time requirements: 

Time by diet group:  Significantly more RD time was required for subjects consuming very low protein diets than for those consuming usual or low protein diets.

Dietary protein intake (estimated from 24 hour UUN excretion) was compared at baseline and follow-up across study groups.  Those in the usual protein diet group increased their protein intake by about 8%.  Those in the low protein group decreased their intake to about 75% of baseline, and those in the very low protein group decreased to around 50% of their baseline intake (statistical analyses not provided). 

Time by sociodemographics and renal diagnosis:  Age, gender, race, marital status, and renal diagnosis did not influence time requirements.  There was a significant inverse association between education level of the subjects and the RD time for counseling in follow-up periods 5-12 months (p<0.05) and 13-24 months (p<0.01). 

Mean time in minutes (+SD) for dietitian activities 

 

Months

1-4   Months 5-12   Months 13-24   Months 25-36
  Usual protein group (n=255) Low protein group (n=347) Very low protein group (n=104) Usual protein group (n=286) Low protein group (n=406) Very low protein group (n=121) Usual protein group (n=274) Low protein group (n=386) Very low protein group (n=108) Usual protein group (n=167) Low protein group (n=228) Very low protein group (n=66)
Counseling 59+25 68+29 74+31** 45+16 51+19 56+19* 38+14 41+16 47+18** 34+14 36+15 41+16
Mean total time 171+68 186+69 204+73** 131+40 146+47 157+56* 120+37 128+43 138+44** 112+39 118+41 118+41

 *p<0.05; **p<0.01 (results from one-way ANOVA)

The first 4 mos of follow-up were the most labor intensive.  Average total time was 183+70 minutes per visit during the first 4 mos and 116+41 minutes per visit during the 3rd year.  Most of the decline was in counseling time, while time for research remained fairly constant at about 30-35 minutes per visit. 
Author Conclusion:

Professional time required to implement effective medical nutrition therapy is a key factor related to cost-effectiveness and cost-benefit analysis.

Time requirements declined over the 3 year period, especially in preparation/follow-up and counseling activities.  Sustained support from the RD helped prevent relapse and improved the participants' application of skills over time.

Greater time requirements were necessary when working with participants who had completed fewer years of education.

The time-log data from this study provide important information for administrators, nutrition professionals, and scientists involved in the treatment and investigation of diet and renal issues. The data have direct application in planning research studies with similar subjects and when determining staffing patterns for nutrition programs aimed at the management of renal disease. This study demonstrates the extensive skills necessary to effectively deliver renal nutrition programs.

Funding Source:
Government: NIDDK, Health Care Financing Administration
Reviewer Comments:

Validation studies for the time-log developed were not conducted, however, several versions of the form were pilot-tested prior to initiation of data collection after the first year of recruitment into the MDRD Study.  Dietitians were trained in research procedures and aware of accurate and complete data collection.

Adherence to dietary protein was estimated using 24 hour UUN excretion data (mean + SD per group).  Using this method, adherence to protein goals was slightly below target for the usual group and somewhat above target for the low and very low groups, although long term adherence to the diet protocol was an emphasis of the Nutrition Intervention Program, through which the data for this time analysis were collected.

Quality Criteria Checklist: Primary Research
Relevance Questions
  1. Would implementing the studied intervention or procedure (if found successful) result in improved outcomes for the patients/clients/population group? (Not Applicable for some epidemiological studies) Yes
  2. Did the authors study an outcome (dependent variable) or topic that the patients/clients/population group would care about? Yes
  3. Is the focus of the intervention or procedure (independent variable) or topic of study a common issue of concern to dieteticspractice? Yes
  4. Is the intervention or procedure feasible? (NA for some epidemiological studies) ???
 
Validity Questions
1. Was the research question clearly stated? Yes
  1.1. Was (were) the specific intervention(s) or procedure(s) [independent variable(s)] identified? Yes
  1.2. Was (were) the outcome(s) [dependent variable(s)] clearly indicated? Yes
  1.3. Were the target population and setting specified? Yes
2. Was the selection of study subjects/patients free from bias? Yes
  2.1. Were inclusion/exclusion criteria specified (e.g., risk, point in disease progression, diagnostic or prognosis criteria), and with sufficient detail and without omitting criteria critical to the study? Yes
  2.2. Were criteria applied equally to all study groups? Yes
  2.3. Were health, demographics, and other characteristics of subjects described? Yes
  2.4. Were the subjects/patients a representative sample of the relevant population? Yes
3. Were study groups comparable? Yes
  3.1. Was the method of assigning subjects/patients to groups described and unbiased? (Method of randomization identified if RCT) Yes
  3.2. Were distribution of disease status, prognostic factors, and other factors (e.g., demographics) similar across study groups at baseline? Yes
  3.3. Were concurrent controls or comparisons used? (Concurrent preferred over historical control or comparison groups.) Yes
  3.4. If cohort study or cross-sectional study, were groups comparable on important confounding factors and/or were preexisting differences accounted for by using appropriate adjustments in statistical analysis? N/A
  3.5. If case control study, were potential confounding factors comparable for cases and controls? (If case series or trial with subjects serving as own control, this criterion is not applicable.) N/A
  3.6. If diagnostic test, was there an independent blind comparison with an appropriate reference standard (e.g., "gold standard")? N/A
4. Was method of handling withdrawals described? Yes
  4.1. Were follow-up methods described and the same for all groups? Yes
  4.2. Was the number, characteristics of withdrawals (i.e., dropouts, lost to follow up, attrition rate) and/or response rate (cross-sectional studies) described for each group? (Follow up goal for a strong study is 80%.) N/A
  4.3. Were all enrolled subjects/patients (in the original sample) accounted for? Yes
  4.4. Were reasons for withdrawals similar across groups? N/A
  4.5. If diagnostic test, was decision to perform reference test not dependent on results of test under study? N/A
5. Was blinding used to prevent introduction of bias? ???
  5.1. In intervention study, were subjects, clinicians/practitioners, and investigators blinded to treatment group, as appropriate? ???
  5.2. Were data collectors blinded for outcomes assessment? (If outcome is measured using an objective test, such as a lab value, this criterion is assumed to be met.) ???
  5.3. In cohort study or cross-sectional study, were measurements of outcomes and risk factors blinded? N/A
  5.4. In case control study, was case definition explicit and case ascertainment not influenced by exposure status? N/A
  5.5. In diagnostic study, were test results blinded to patient history and other test results? N/A
6. Were intervention/therapeutic regimens/exposure factor or procedure and any comparison(s) described in detail? Were interveningfactors described? Yes
  6.1. In RCT or other intervention trial, were protocols described for all regimens studied? Yes
  6.2. In observational study, were interventions, study settings, and clinicians/provider described? N/A
  6.3. Was the intensity and duration of the intervention or exposure factor sufficient to produce a meaningful effect? Yes
  6.4. Was the amount of exposure and, if relevant, subject/patient compliance measured? Yes
  6.5. Were co-interventions (e.g., ancillary treatments, other therapies) described? Yes
  6.6. Were extra or unplanned treatments described? N/A
  6.7. Was the information for 6.4, 6.5, and 6.6 assessed the same way for all groups? Yes
  6.8. In diagnostic study, were details of test administration and replication sufficient? N/A
7. Were outcomes clearly defined and the measurements valid and reliable? Yes
  7.1. Were primary and secondary endpoints described and relevant to the question? Yes
  7.2. Were nutrition measures appropriate to question and outcomes of concern? Yes
  7.3. Was the period of follow-up long enough for important outcome(s) to occur? Yes
  7.4. Were the observations and measurements based on standard, valid, and reliable data collection instruments/tests/procedures? Yes
  7.5. Was the measurement of effect at an appropriate level of precision? ???
  7.6. Were other factors accounted for (measured) that could affect outcomes? No
  7.7. Were the measurements conducted consistently across groups? Yes
8. Was the statistical analysis appropriate for the study design and type of outcome indicators? Yes
  8.1. Were statistical analyses adequately described and the results reported appropriately? Yes
  8.2. Were correct statistical tests used and assumptions of test not violated? Yes
  8.3. Were statistics reported with levels of significance and/or confidence intervals? Yes
  8.4. Was "intent to treat" analysis of outcomes done (and as appropriate, was there an analysis of outcomes for those maximally exposed or a dose-response analysis)? N/A
  8.5. Were adequate adjustments made for effects of confounding factors that might have affected the outcomes (e.g., multivariate analyses)? No
  8.6. Was clinical significance as well as statistical significance reported? Yes
  8.7. If negative findings, was a power calculation reported to address type 2 error? N/A
9. Are conclusions supported by results with biases and limitations taken into consideration? Yes
  9.1. Is there a discussion of findings? Yes
  9.2. Are biases and study limitations identified and discussed? Yes
10. Is bias due to study's funding or sponsorship unlikely? Yes
  10.1. Were sources of funding and investigators' affiliations described? ???
  10.2. Was the study free from apparent conflict of interest? Yes